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Abstract
Despite more than three decades of intensive effort, no effective pharmacologic inhibitors of the 
Ras oncoproteins have reached the clinic, prompting the widely held perception that Ras proteins 
are “undruggable”. However, there is renewed hope that this is not the case. In this review, we 
summarize the progress and promise of five key directions. First, we focus on the prospects of 
direct inhibitors of Ras. Second, we revisit the issue of whether blocking Ras membrane 
association is a viable approach. Third, we assess the status of targeting Ras downstream effector 
signalling, arguably the most favourable current direction. Fourth, we address whether the search 
for synthetic lethal interactors of mutant RAS still holds promise. Finally, Ras-mediated changes in 
cell metabolism have recently been described. Can these changes be exploited for new therapeutic 
directions? We conclude with perspectives on how additional complexities, not yet fully 
understood, may impact each of these approaches.
Introduction
In 1982 mutationally activated RAS genes were detected in human cancers, marking the first 
discovery of mutated genes in this disease1. Subsequent intensive sequencing of the cancer 
genome has revealed that, despite the identification of over 500 validated cancer genes2 
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(COSMIC), the three RAS genes (HRAS, NRAS and KRAS) still comprise the most 
frequently mutated oncogene family in human cancers (TABLE 1; SUPPLEMENTARY 
TABLES 1 and 2). The frequent mutation of RAS in three of the top four cancer killers in the 
US (lung, colon, pancreatic) has spurred intense interest and effort in developing Ras 
inhibitors. However, despite more than three decades of effort by academia and industry, no 
effective anti-Ras inhibitors have reached the clinic, prompting a widely held perception that 
Ras oncoproteins are an “undruggable” cancer target. Although past failures dampened 
enthusiasm for anti-Ras drug discovery, mutated Ras proteins clearly merit continued 
attention. Given that the greatest success in signal transduction-based therapies has been 
achieved against mutationally activated targets, there is now renewed hope that recent 
advances in understanding Ras function, together with new approaches and technology, may 
finally have brought the holy grail of cancer research within reach3.
In this review, we provide a critical assessment of past efforts and discuss the most 
promising directions for future success (FIG. 1). First, we begin with what was once thought 
impossible: direct inhibition of Ras. Second, we discuss the prospects for blocking Ras 
membrane association, a direction that had lost favour with the disappointing outcome of 
farnesyltransferase inhibitors4. Third, we provide a status report on inhibitors of Ras 
downstream effector signalling, in particular through Raf and phosphoinositide 3-kinase 
(PI3K). Fourth, we summarize the efforts in the search for synthetic lethal interactors with 
mutant RAS and discuss whether this direction might yield alternative targets. We next 
evaluate the prospect that Ras-mediated changes in cell metabolism can be exploited for 
drug discovery. We conclude with a discussion of unresolved issues that will likely add 
complexity and further challenges to anti-Ras drug discovery.
RAS mutations and human cancer
RAS mutations are early genetic events in tumour progression. Numerous genetically 
engineered mouse models of RAS-driven cancers have demonstrated the potent cancer-
inducing activity of mutant RAS. Consistent with the need for additional genetic alterations 
to cooperate with mutant RAS for full transforming activity, loss of tumour suppressor 
function (e.g., TP53, LKB1, APC) together with RAS activation results in enhanced tumour 
formation and progression5–7. Despite the early onset of RAS mutations, there is 
considerable experimental evidence that continued expression of mutant RAS is necessary 
for tumour maintenance. Suppression of RAS by RNA interference impaired the in vitro and 
in vivo growth of RAS-mutant human cancer cell lines8–10. Similarly, in mouse models 
driven by inducible mutant RAS, withdrawal of Ras expression leads to tumour 
regression11–15. Hence, there is little doubt that mutant Ras is a therapeutically useful drug 
target even in advanced metastatic tumours. Until recently, RAS-mutant cancers were 
discussed as if they comprised a homogeneous subset of all cancers. Instead, there is now an 
emerging understanding that not all mutant RAS genes are created equal. Both the frequency 
with which each RAS isoform is mutated and the specific mutations thereof vary strikingly 
in different cancer types (BOX 1), and these may need to be addressed differently. Thus, 
there may not be one single anti-Ras therapy that fits all RAS-mutant cancers.
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RAS mutations in human cancer
The frequency and distribution of RAS gene mutations are not uniform1,191. KRAS is the 
isoform most frequently mutated (86%), followed by NRAS (11%), and, infrequently, 
HRAS (3%) (COSMIC) (SUPPLEMENTARY TABLE 1). Overall, RAS mutations have 
been detected in 9–30% of all tumour samples sequenced (depending on the database 
utilized), with the specific RAS isoform generally differing according to cancer type. In 
pancreatic ductal adenocarcinoma (PDAC; ~90% of all pancreatic cancers) and lung 
adenocarcinoma (LAC; 30–35% of all lung cancers) there is a near 100% frequency of 
KRAS mutations. In colon and rectal carcinomas (CRC), KRAS is also the predominant 
mutated isoform (86%), whereas NRAS mutations are infrequent (14%) and HRAS 
mutations have not been detected. Conversely, KRAS and NRAS are seen at equivalent 
frequencies in multiple myeloma (MM), and NRAS is the predominant isoform mutated 
in cutaneous melanomas (94%) and acute myelogenous leukaemias (AML; 59%). 
Although rare overall, HRAS mutations are predominant in bladder (57%) and in head 
and neck squamous cell carcinomas (HNSCC; 86%).
Cancer-associated RAS genes are characterized by single base missense mutations, 99% 
of which are found at residues G12, G13 or Q61. There are also cancer-type differences 
in the relative frequency of mutations at these positions. In PDAC and NSCLC, KRAS 
mutations are found predominantly at G12. In CRC, G12 is also the predominant position 
(78%), but additionally there is a significant frequency of G13 mutations (20%), of 
mutations at A146, a position rarely mutated in other cancers, and, to a lesser frequency, 
at K117. There are also cancer-type differences in the substitutions seen at a given 
residue. For example, at G12, in PDAC and CRC the predominant substitution is G12D, 
followed by G12V. In contrast, in NSCLC, the major substitution is G12C, which is rare 
in PDAC.
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The basics: in search of the Achilles’ heel of Ras
In order to develop antagonists of Ras, it is essential to understand the requirements for Ras 
function. The canonical property of Ras is that of a small GTPase which normally cycles 
between a GTP-bound active state and a GDP-bound inactive state, facilitated in part by 
GTPase activating protein (GAP) stimulation of GTP hydrolysis. However, when Ras 
proteins are mutationally activated, impaired GAP stimulation favours the formation of 
persistently GTP-bound Ras16 (BOX 2). This critical biochemical defect prompted the 
earliest efforts to target mutant Ras. By analogy to the ATP-competitive inhibitors that are 
effective antagonists of protein kinases, identification of GTP-competitive inhibitors of Ras 
has been attempted. However, whereas ATP binds protein kinases with low micromolar 
affinity, GTP binds Ras proteins with picomolar affinity, preventing discovery of effective 
inhibitors. Another early effort searched for small molecules that could act as GAPs for 
mutant Ras. To date, these efforts have not succeeded17.
Box 2
Regulation of the Ras GDP-GTP cycle
The three RAS genes encode four 188–189 amino acid proteins that share 82–90% overall 
sequence identity (blue vertical line indicates amino nonidentity). KRAS encodes two 
splice variants that result from alternative exon 4 utilization, encoding divergent C-
terminal sequences. Exons 4A and 4B encode 39 and 38 amino acids, respectively, with 
19 identical and 4 conserved substitutions. K-Ras4A is most similar to the original 
retroviral K-Ras while K-Ras4B is the predominant isoform expressed in human cells. 
Residues in Switch I (SI; aa 30–38) and II (SII; aa 60–76) change in conformation during 
GDP-GTP cycling. Wild type Ras proteins bind GDP and GTP with low picomolar 
affinities. With cellular levels of GDP and GTP at millimolar concentrations, Ras is 
persistently nucleotide-bound. Ras proteins possess low intrinsic GTP hydrolysis and 
guanine nucleotide exchange activities, which are regulated and accelerated by GTPase 
activating proteins (RasGAPs) and guanine nucleotide exchange factors (RasGEFs), 
respectively. In resting cells, Ras is predominantly GDP-bound. Upon growth factor 
stimulation and activation of RasGEFs, nucleotide binding is destabilized and the 
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nucleotide is released. Since the cellular concentrations of GTP are 10-fold that of GDP, 
RasGEFs promote transient formation of Ras-GTP, with RasGAPs returning the protein 
to the inactive GDP-bound state. Mutant Ras is impaired in intrinsic and GAP-stimulated 
GTP hydrolysis activity, favouring persistent formation of Ras-GTP.
Another key requirement for Ras function is its association with the inner face of the plasma 
membrane18 (BOX 3), for which it is obligatory that Ras be modified by addition of a C15 
farnesyl isoprenoid lipid to its C-terminal CAAX motif. The identification of 
farnesyltransferase (FTase) and the determination that the C-terminal CAAX tetrapeptide 
sequence alone was sufficient to inhibit FTase activity19 prompted an intensive effort to 
develop FTase inhibitors (FTIs)4. Many potent and selective FTIs were shown in preclinical 
mouse studies to effectively block the growth of Hras-driven tumours. These remarkable 
results led to clinical trials, with two FTIs (lonafarnib and tipifarnib) advancing to Phase III. 
However, these FTIs showed no anti-tumour activity in clinical trials focused on pancreatic 
and colon cancers, which are associated with mutations in KRAS or NRAS rather than HRAS 
(TABLE 1, BOX 1). One basis for this failure was predicted years earlier when it was found 
unexpectedly that, when FTase activity is blocked by FTI treatment, K-Ras4B and N-Ras 
proteins are no longer farnesylated but instead become substrates for the related 
prenyltransferase geranylgeranyltransferase-I (GGTase I) that catalyses addition of a C20 
geranylgeranyl isoprenoid group20–22. Since this alternate lipid can also support their 
membrane association and oncogenic activities, K-Ras4B and N-Ras escape FTI-mediated 
inhibition of their function. The failure of this massive effort to develop FTIs as anti-Ras 
drugs created a stigma towards other ideas for blocking Ras membrane association. Worse, 
the failure of FTIs to act as anti-Ras drugs also prompted a surprisingly widely held 
misconception that Ras is not a useful therapeutic target. It did create large clues that 
conflating all the Ras isoforms together would be an unfortunate oversimplification.
Box 3
Posttranslational modifications that regulate Ras membrane association 
and subcellular localization
Ras proteins are synthesized initially as cytosolic and inactive proteins. All four Ras 
proteins terminate in a C-terminal CAAX tetrapeptide motif comprised of an invariant 
Cox et al. Page 5













cysteine residue to which the lipid is attached, followed by two typically aliphatic 
residues (AA), and the C-terminal residue (X) that contributes to prenyltransferase 
substrate specificity. The CAAX motif is necessary and sufficient to signal a series of 
posttranslational modifications that enhance the hydrophobicity of Ras, facilitating 
membrane association. The first step is catalysed by cytosolic farnesyltransferase 
(FTase)-mediated covalent addition of a C15 farnesyl isoprenoid to the cysteine of the 
CAAX motif, followed by Ras converting enzyme 1 (Rce1)-catalysed proteolytic 
removal of the AAX peptide, and finally isoprenylcysteine methyltransferase (ICMT)-
catalysed carboxylmethylation of the now terminal farnesylated cysteine. FTase 
inhibitors (FTIs) prevent all three modifications. All Ras proteins are modified by FTase 
in cells. However, upon FTase inhibition by FTI treatment, K-Ras4B and N-Ras can be 
modified instead by addition of a C20 geranylgeranyl isoprenoid by the related enzyme 
geranylgeranyltransferase I (GGTase I). The CAAX-signalled modifications alone are 
not sufficient to promote Ras trafficking and association with the inner face of the plasma 
membrane. Ras proteins possess a second membrane targetting element comprised of 
either a polybasic amino acid stretch (K-Ras4B) or cysteine residues that undergo 
reversible acylation by the fatty acid palmitate.
The third key requirement for Ras function is the engagement of effector proteins that 
transmit signals downstream. The GTP-bound form of Ras is the active form by virtue of its 
increased affinity for effectors. Presently, at least 11 distinct classes of Ras effectors have 
been identified. The majority of these possess Ras-binding (RBD) or Ras-association (RA) 
domains23. Association with Ras-GTP promotes effector activation by promoting 
concentration at the plasma membrane, where additional events facilitate activation and/or 
enhance intrinsic catalytic activity. Genes encoding members of the two canonical Ras 
effector families, BRAF and PIK3CA, are also frequently mutationally activated in human 
cancers (20% and 12%, respectively; COSMIC) (SUPPLEMENTARY TABLE 1), 
supporting the importance of these pathways in driving cancer growth. Additionally, cell 
culture and mouse model studies have established driver roles for at least four other Ras 
effectors1. In light of the critical requirement for effector signalling in mutant Ras function, 
most current efforts to develop anti-Ras therapies have centered on pharmacologic inhibitors 
of effector signalling, as described below.
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In the following sections, we summarize progress made in five key approaches to target Ras. 
We note that, since almost none of these approaches is selective for mutant Ras, additional 
future strategies that do not rely on selective Ras-dependency may be required to enhance 
the therapeutic index for cancer cells.
Direct inhibitors of Ras – druggable after all?
Direct targeting of Ras has been thought to be a very challenging task, if not downright 
impossible. Although some potential binding sites have been identified using computational 
approaches24,25, there do not appear to be any deep hydrophobic pockets on the surface of 
K-Ras that would allow tight binding of small molecules. Nevertheless, there have been 
several attempts to discover small molecules that bind directly to Ras26. This section 
describes these efforts.
Low-affinity inhibitors
One of the first compounds reported (SCH-53239, FIG. 2) was designed to compete with 
GDP for the nucleotide binding site of Ras27. Instead of binding in this fashion, a water-
soluble analog (SCH-54292, FIG. 2) was found by NMR spectroscopy to bind to a 
hydrophobic pocket near the switch II (SII) region of Ras (BOX 2), with the hydroxylamine 
located near the Mg2+ cation on the basis of the intermolecular NOEs involving I100 and 
R68 of Ras27. Additional compounds were prepared in which the sugar of SCH-54292 was 
replaced with a bicyclic moiety based on molecular modeling (bicyclic analog, FIG. 2) that 
inhibited nucleotide exchange similarly to the originally described molecules within this 
series28. Two of these analogs also inhibited Ras-dependent cell growth. However, all of the 
compounds from this series contain a hydroxylamine, which appears to be critical for their 
activity but is not an ideal functional group in a drug molecule due to its toxicity and poor 
metabolic stability. Furthermore, these compounds are not very potent.
Another series of compounds that have been reported to noncovalently bind to Ras and to 
inhibit Ras/Raf complex formation was based on the non-steroidal anti-inflammatory drug, 
sulindac sulphide29 (FIG. 2). Sulindac analogs were synthesized, and the most potent was 
shown to bind to Ras at the Raf binding site when complexed with the nonhydrolysable GTP 
analog, GppNHp30. In addition, this compound inhibited the Ras-Raf interaction with an 
IC50 of 30 μM and decreased downstream phosphorylation of ERK (see FIG. 4 for 
pathway). The sulindac derivative IND12 selectively inhibited the proliferation of Ras-
transformed cells31, induced the expression of E-cadherin, and increased the level of E-
cadherin-bound β-catenin, thereby decreasing invasion32. However, none of the sulindac 
series of compounds are thus far potent enough to serve as useful drug molecules, and it is 
unclear whether the other off-target activities of sulindac and its derivatives would prove to 
be problematic.
In a yeast two-hybrid screen for other compounds that would inhibit the Ras-Raf interaction, 
small molecules (e.g., MCP1, FIG. 2, and later derivatives) were discovered that inhibited 
Raf activation in cancer cells and reversed Ras-transformed phenotypes33,34. Again, the 
compounds were not very potent. Structural information on how they bind has not yet been 
obtained but could be useful for improving their potency if it becomes available. For Zn2+ 
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cyclen (FIG. 2), structural information has been reported on how it binds to Ras and blocks 
the Ras-Raf interaction35, but due to its lack of selectivity for binding proteins and chelating 
different metals, Zn2+ cyclen also does not represent a good starting point for the design of 
drug-like molecules. Nevertheless, this work revealed the existence of at least two distinct 
conformational states of Ras when bound to GTP analogs and demonstrated the possibility 
of stabilizing one of these conformations to inhibit effector interactions.
GEF inhibitors
The Ras GTP/GDP cycle is regulated negatively by GAPs and positively by GEFs, or 
guanine nucleotide exchange factors, that facilitate the dissociation of GDP and thereby 
promote binding of the more abundant GTP moiety (BOX 2). The most prominent RasGEF 
is Sos1, which has multiple binding sites for Ras. In addition to the small organic molecules 
that bind to Ras, a peptide based on the αH helix of the Sos1 RasGEF, the region that forms 
contacts with Ras (HBS3 peptide; FIG. 2), was found to bind directly to Ras in a cleft near 
the SI and SII regions36. The new peptide was designed to be more water soluble than the 
Sos αH peptide and to have improved helical character. To do this, the hydrogen bond 
surrogate approach was used, in which the N-terminal hydrogen bond between the carbonyl 
of the ith amino acid and the amine of the i+4th amino acid was replaced with a carbon-
carbon bond. This peptide bound to GDP-bound Ras with a Kd of 158 μM, inhibited Ras 
activation, and regulated ERK-MAPK signalling in cells. Although the reported peptide was 
not very potent, further optimization of the helical peptide could lead to drug-like molecules, 
as was recently demonstrated for stapled helix peptides targeting challenging protein-protein 
interactions37.
In 2012, two groups reported on K-Ras4B binders that were discovered from fragment-
based screening38,39. The group from Genentech identified a compound called DCAI (FIG. 
2) which was shown to bind to a pocket located between the α2 helix and β sheet of K-Ras, 
as revealed by an X-ray structure of the co-complex (FIG. 3a). DCAI weakly inhibited Sos-
mediated nucleotide exchange (IC50 = 340 μM) by blocking the interaction between Ras and 
Sos, and inhibited Ras activation in cells. Independently, the Vanderbilt group discovered 
several series of fragment hits in an NMR-based screen of 11,000 compounds that bind 
weakly to GDP-bound K-Ras. The X-ray structures of several of these hits and of their water 
soluble analogs bound to K-Ras indicated that they all bind to the same pocket: the same site 
where DCAI binds to the protein (FIG. 3b). This pocket is not readily observed in the 
ligand-free form of K-Ras. Instead, compound binding induces a conformational change in 
the protein in which Tyr71 moves out of the way, along with Met67 and α2 of the SII 
region, to create a primary binding pocket and a second nearby cleft39. From the structural 
information obtained from the X-ray data, additional compounds were designed and 
synthesized with improved affinity (e.g., VU0460081, Kd = 240 μM) compared to the initial 
fragment hits, but were still not very potent. Nevertheless, these compounds inhibited Sos-
mediated nucleotide exchange by blocking Ras-Sos complex formation, as evidenced by a 
series of NMR experiments. Importantly, detailed structural information on how multiple 
small molecules bind to K-Ras were obtained from these studies. However, like many other 
previously reported compounds, the small molecules reported in these two papers bind only 
weakly to K-Ras, and the discovery of analogs with large improvements in affinity is likely 
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to be a very challenging task. Also, even if this can be accomplished, whether compounds 
with such a mechanism of action would be advantageous in the setting of mutationally 
active Ras proteins is currently controversial.
Inhibitors of Raf-1 binding
In another study, using a computer docking screen of a virtual library of compounds, several 
small molecules were selected for their ability to inhibit Ras-GTP binding to the Ras binding 
domain of Raf-140. One compound (Kobe 0065, FIG. 2) was identified that inhibited this 
interaction with a Ki = 46 μM, and another (Kobe 2602, FIG. 2) with a Ki = 149 μM was 
obtained from a subsequent similarity search. In cells, these compounds decreased the 
phosphorylation of downstream proteins in the Ras pathway, including MEK, ERK, and 
AKT, and inhibited the allosteric Ras binding site of Sos. In addition, the compounds 
inhibited colony formation of NIH 3T3 mouse fibroblasts and several different human 
cancer cell lines in soft agar, blocked the proliferation of H-Ras G12V-transformed NIH 
3T3 cells, and inhibited tumour growth in a xenograft tumour model in nude mice. On the 
basis of NMR data, the compounds were postulated to bind to a site near the SII region of 
Ras in a similar but not identical pocket as the Genentech and Vanderbilt compounds (FIG. 
3c). The Kobe compounds bind onto the surface on the side of the α2 helix. Although the 
compounds are not very potent, it was suggested that they may serve as a scaffold for the 
discovery of analogs with higher potency and selectivity. However, to be useful starting 
points for lead optimization, a suitable replacement for the toxic thiosemicarbazide scaffold 
would have to be found.
Mutant-specific inhibitors
Another interesting study recently described a very novel approach for targeting Ras41. 
Shokat and colleagues reported on small molecules that covalently bind selectively to the 
G12C mutant form of K-Ras, which is the most frequent RAS mutation found in non-small 
cell lung cancer (BOX 1). These compounds were discovered by screening a library of small 
molecules with GDP-bound K-Ras G12C using a tethering approach, followed by the design 
and synthesis of analogs guided by X-ray structures of co-complexes (FIG. 3d). The 
compounds were found to bind to a pocket between the α2 and α3 helices, on the other side 
of the SII region from the Genentech and Vanderbilt compounds, but at a site similar to 
where SCH-54292 was postulated to bind to K-Ras based on NMR data. As predicted, these 
compounds blocked Sos-mediated nucleotide exchange and decreased the binding of Ras to 
both B-Raf and C-Raf. Interestingly, they also appeared to selectively kill cancer cells 
harbouring the G12C mutation (K-Ras (G12C) inhibitor, FIG 2). Lung cancer aside, the 
G12C mutation is found in only a small subset of cancers compared to other K-Ras 
mutations (BOX 1), and it may be difficult to selectively target other commonly found 
mutations. However, this work demonstrates that it is possible to selectively target the G12C 
mutant form of Ras over the wild type protein. This could result in compounds with low 
toxicity, providing that small molecules could be discovered that do not bind to other 
cysteine-containing proteins. In other studies aimed at covalent attachment to cysteine-
containing proteins, compounds lacking the electrophile that forms the irreversible bond 
typically bind very tightly to the protein42,43. For the K-Ras inhibitors in this study, 
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however, fragments lacking the electrophile do not appear to bind to K-Ras G12C, 
suggesting that it might be difficult to achieve the needed selectivity.
Gray and co-workers have also targeted K-Ras G12C. They prepared a GDP analog with an 
attached electrophile (SML-8-73-1) that could covalently bind to the cysteine of the G12C 
mutant form of K-Ras44. Although small molecules targeting the guanine nucleotide binding 
site have been disregarded due to the picomolar affinity of GTP and GDP to K-Ras and their 
high intracellular concentration, SML-8-73-1 was shown to covalently bind K-Ras G12C 
even in the presence of 1 mM concentrations of GDP and GTP. In addition, a cell-permeable 
analog was shown to attenuate the downstream phosphorylation of AKT and ERK and to 
exhibit antiproliferative effects in several cell lines44.
Despite the many attempts to directly target K-Ras that have been published thus far, K-Ras 
still remains a very challenging target. Although some progress has been made in the 
identification of different compounds that weakly bind to Ras, the binding affinity of these 
early stage compounds would have to be markedly improved for them to be useful as drugs. 
In principle, this might be accomplished by linking these molecules together, providing that 
the linked compounds could possess drug-like properties. Alternatively, a different approach 
may be required, such as the targeting of a Ras/protein interface in which more suitable 
binding pockets may be present. In this regard, small molecules have been identified that 
bind to a hydrophobic pocket in the Ras:Sos1:Ras complex that is formed by the CDC25 
homology (RasGEF) catalytic domain of Sos1 adjacent to the SII region of Ras45 (FIG. 2; 
Nucleotide exchange activator/compound 4). These compounds were shown to increase the 
rate of SOS-catalyzed nucleotide exchange and, as expected, increase the levels of Ras-GTP. 
However, paradoxically, they cause a biphasic response in the MAPK pathway with 
inhibition of ERK phosphorylation at high compound concentration, and they inhibit PI3K 
signalling as evidenced by a decrease in AKT phosphorylation. These compounds decrease 
cell proliferation and anchorage-independent growth, and suggest another possible approach 
to target Ras signalling for the treatment of Ras-driven tumours.
Inhibitors of membrane association/subcellular localization – back to the 
future?
Farnesyl transferase inhibitors
Although FTIs are not effective against the Ras isoforms most commonly mutated in human 
cancers, there is continued discussion as to whether FTIs can still be an effective therapeutic 
approach for HRAS-mutant cancers46 such as thyroid, bladder, head and neck, and skin 
cancers (TABLE 1 and BOX 1). However, even in these cancers, the HRAS mutation 
frequency is low and the driver function of HRAS and hence the potential therapeutic value 
of anti-HRAS drugs remains to be vigorously evaluated. Since the future of cancer treatment 
is personalized medicine and full exome sequencing, if HRAS is ultimately validated as a 
cancer driver, then a rigorous assessment of whether HRAS-mutant cancers are responsive to 
FTIs should be done.
The disappointing clinical outcome of FTIs in KRAS-mutant cancers extinguished interest in 
the further pursuit of anti-Ras strategies targeting Ras membrane association4. Thus, while 
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observations from genetic studies in a KrasG12D-driven lung cancer mouse model 
suggested that combination treatment strategies to concurrently block both FTase and 
GGTase-I can be effective and might not be overtly deleterious47, there remain considerable 
caution and lack of interest in this approach. This lack of interest is based in part on the 
perception that concurrent inhibition of both enzymes, that collectively may have up to 300 
substrates4, will be limited by serious toxicity in normal tissues overall, a point not 
addressed by the genetic studies cited above.
Another therapeutic approach that targets the farnesyl modification is salirasib/S-
farnesylthiosalicylic acid (FTS), which acts as a mimic of the C-terminal S-farnesyl cysteine 
modification of Ras. The specific consequences of salirasib treatment on Ras function are 
varied and include decreased plasma membrane association, decreased Ras-GTP levels and 
protein stability, and decreased effector signalling48–50. Salirasib can also impair the 
activities of other farnesylated proteins (e.g., Rheb)51 and mTOR, through a mechanism that 
is not clearly understood52,53. Based on positive preclinical results in pancreatic cancer 
mouse models54,55, a clinical trial was performed in pancreatic cancer patients56. Although 
tantalizingly there were some longterm survivors, the main conclusion that could be reached 
definitively was that the treatment was well-tolerated. Unfortunately, the patient numbers 
were too small to determine if a significant clinical benefit was gained and if K-Ras function 
was effectively perturbed. Further clinical evaluation is merited, but better understanding of 
the key mechanism(s) of FTS action and of accurate biomarkers to monitor target inhibition 
are also needed.
Inhibitors of Rce1 and ICMT
While there has been some interest in developing inhibitors of the two other CAAX-
signalled Ras processing enzymes, Rce1 and ICMT (BOX 3), concern that they are likely 
also required for the function of other proteins with critical roles in normal cell physiology 
has limited enthusiasm for discovery efforts. For example, the 19 ICMT substrates in the 
CXC-terminating Rab family of small GTPases are critical for regulating vesicular transport. 
Thus, pharmacologic inhibition of either Rce1 or ICMT activity will almost certainly impact 
the functions of many proteins beyond Ras, and consequently normal tissue toxicity may 
well be a limitation for these two targets.
In addition, although earlier studies in Rce1- or Icmt-deficient mouse embryo fibroblasts 
(MEFs) revealed impairment in H-Ras-mediated transforming activity, subsequent studies 
found more complex consequences of the loss of these enzymes. For example, Rce1 ablation 
concurrent with KrasG12D activation in mouse hematopoietic cells enhanced 
myeloproliferative disease57. In contrast, Icmt ablation in the same mouse model reduced 
myeloproliferative disease58. However, Icmt ablation concurrent with KrasG12D activation 
in the pancreas exhibited increased PanIN formation and accelerated neoplastic 
progression59. One logical explanation for these results is that both Rce1 and ICMT may 
possess up to 300 CAAX-terminating substrates in addition to Ras, and that these substrates 
may be differentially sensitive to enzyme inhibition, depending on context. Furthermore, 
while cell-active small molecules have been identified and characterized60–62, potent and 
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selective pharmacologic inhibitors of Rce1 and ICMT suitable for in vivo analyses have yet 
to be identified.
Inhibiting palmitoylation/depalmitoylation
Another lipid modification that has attracted some interest is palmitoylation. Modification 
by the fatty acid palmitate is essential for the plasma membrane association and function of 
H-Ras and N-Ras, and likely K-Ras4A. These Ras isoforms are reversibly and covalently 
modified by one or two palmitoyl fatty acids on cysteines immediately upstream of the 
CAAX motif. Studies with nonpalmitoylated variants of H-Ras and N-Ras support the 
importance of this modification in Ras-driven oncogenesis63,64. One human palmitoyl 
acyltransferase (DHHC9/GCP16) has been described as having activity towards H-Ras and 
N-Ras65. However, since K-Ras4B is not palmitoylated, this approach will not be useful for 
the majority (85%) of RAS-mutant cancers. Another approach is suggested by the dynamic 
acylation/reacylation cycle of Ras, wherein depalmitoylation, perhaps counterinteruitively, 
promotes Ras redistribution to membrane sites where it is active66–68. Thus, 
depalmitoylation inhibitors have been proposed as a means of inhibiting Ras membrane 
association and function69. Given that there are currently 24 known mammalian palmitoyl 
acyltransferases70, it is unclear whether DHHC9/GCP16 is the only member with activity 
towards Ras proteins, how selective it is for Ras, and whether DHHC9/GCP16-selective 
inhibitors can be developed. It has also not yet been shown definitively whether the 
observed cellular consequences of depalmitoylation inhibitors are due to inhibiting Ras 
depalmitoylation. These issues, together with the potential for off-target activities of these 
inhibitors on non-Ras substrates, are concerns that currently diminish enthusiasm for this 
direction.
Inhibitors of other posttranslational modifications
Other posttranslational modifications that can regulate Ras subcellular localization and/or 
effector interactions have also attracted interest as possible directions for anti-Ras drug 
discovery. In particular, a classical protein kinase C, PKCα, catalyses phosphorylation of K-
Ras4B at S181 within the C-terminal polybasic sequence. This phosphorylation causes Ras 
to dissociate from the plasma membrane and move to endomembranes71, where it interacts 
with inositol triphosphate receptors (InsP3) on the endoplasmic reticulum. This converts K-
Ras4B from a growth-promoting to growth-suppressing protein, in a Bcl-xL-dependent 
fashion72. The InsP3 interaction blocks the ability of Bcl-xL to potentiate the InsP3-
regulated flux of calcium from ER to mitochondria, which is required for efficient cell 
survival. Whether this process can be exploited for anti-cancer therapy by promoting K-
Ras4B phosphorylation on this residue is an intriguing but unrealized possibility. The goal is 
supported by findings that the PKC agonist bryostatin-1 can cause K-Ras4B phosphorylation 
and translocation to endomembranes where it drives growth suppression, and that mouse 
tumour xenograft growth was impaired by bryostatin-1 treatment in an S181-dependent 
manner71. Bryostatins have been shown to be well-tolerated in vivo and anti-tumour activity 
has been described73. One obvious concern is that PKCs have numerous substrates and 
therefore pharmacologic approaches to activate PKC will very likely have significant 
consequences unrelated to Ras phosphorylation. Surprisingly, in contrast to these studies, 
fundamentally similar analyses by another group reached the opposite conclusions, 
Cox et al. Page 12













proposing instead that S181 phosphorylation is required for K-Ras4B-mediated cancer 
growth74. A possible basis for these opposing conclusions has not been addressed.
Another intriguing target is endothelial nitric oxide synthase (eNOS)-catalysed nitrosylation. 
This posttranslational modification at Cys118 causes activation of wild type Ras proteins, 
and may promote activities required for cancer growth driven by mutant K-Ras75. Evidence 
supporting eNOS as a possible therapeutic target comes from mouse model studies in which 
genetic ablation of eNOS in the KrasG12D/Tp53 (KPC) mouse model of pancreatic cancer 
prolonged survival76. Treatment with the eNOS-preferential small molecule inhibitor N(G)-
nitro-L-arginine methyl ester (L-NAME) also impaired the growth of human pancreatic cell 
line xenografts and somewhat increased survival in KPC mice76.
A different approach to impairing Ras membrane association was suggested by the 
discovery of proteins that selectively recognize the farnesylated forms of Ras. Of these, 
phosphodiesterase 6 delta (PDE6δ) has attracted particular interest. PDE6δ, which plays a 
role in photoreceptor signalling, interacts with and regulates the trafficking of the PDE6 
complex, which is comprised of both farnesylated and geranylgeranylated subunits77. 
PDE6δ can also recognize K-Ras4B and other prenylated proteins and facilitate their 
trafficking to membrane compartments78. Palmitoylation of H-Ras, N-Ras and K-Ras4A 
prevents their recognition by PDE6δ78. Recently, a small molecule that inhibits the binding 
of PDE6δ to K-Ras4B was shown to impair accumulation of K-Ras4B on the plasma 
membrane and reduce the growth of KRAS-mutant tumour cells79. While these findings are 
intriguing, discrepancies regarding the degree of K-Ras4B dependency on PDE6δ to drive 
cancer growth and whether PDE6δ function is critical for CAAX-terminating proteins 
modified by geranylgeranylation will need to be resolved in order to determine the potential 
therapeutic value of anti-PDE6δ inhibitors80.
Finally, additional posttranslational modifications of Ras that modulate Ras function include 
mono-ubiquitination of H-Ras81 and of K-Ras82, polyubiquitination of K-Ras83 and 
acetylation of K-Ras4B84. However, the enzymology of these modifications, the 
significance of their low stoichiometry, and their potential value as therapeutic targets 
remain unresolved.
Inhibitors of Ras effector signalling – currently our best bet?
There are at least 11 Ras effector families identified to date, with mutation data and 
functional studies validating a contribution of at least six of them to Ras-dependent cancer 
initiation and/or maintenance23,85. In turn, with evidence for a key driver role in Ras-
mediated oncogenesis86,87 the Raf serine/threonine kinases (A-Raf, B-Raf and C-Raf/Raf-1) 
are arguably the most important effectors of mutant RAS-dependent cancer growth. The 
frequent mutational activation of BRAF (SUPPLEMENTARY TABLE 1, and its infrequent 
co-occurrence with RAS mutations, also provides compelling evidence for a driver role for 
Raf in RAS-mutant cancers.
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The only well-validated substrates of Raf are the highly related MEK1 and MEK2 dual 
specificity protein kinases (80% identity), and the only well-validated MEK1/2 substrates 
are the highly related ERK1 and ERK2 serine/threonine kinases (86% identity). These 
findings gave rise to the early perception that this protein kinase cascade is a simple linear 
and unidirectional signalling pathway. However, it is now well-established that the Raf-
MEK-ERK cascade is the core of a complex signalling network with multiple inputs and 
outputs, with feed-forward and feedback mechanisms, and with multiple scaffold proteins 
that dynamically regulate signalling and ERK activity88. The more than 200 substrates that 
have been defined for ERK1/2 alone88 add further complexity to this effector pathway. 
Perhaps not surprisingly then, the earlier assumptions that pharmacologic inhibition of ERK 
activation at the level of either Raf or MEK would be equivalent, and would be effective to 
block ERK activation driven by mutant Ras, have proven incorrect.
Presently, at least 11 pharmacologic inhibitors of Raf kinases have reached clinical 
evaluation, with four approved for use by the US Food and Drug Administration (FDA) 
(FIG. 4). Although sorafenib was developed originally as a Raf inhibitor89, the anti-tumour 
efficacy of this multikinase inhibitor is more likely based on its ability to block tyrosine 
kinases involved in tumour angiogenesis, such as members of the vascular endothelial 
growth factor receptor (VEGFR) family90. Two ATP-competitive Raf inhibitors, 
vemurafenib and dabrafenib, are approved for use in BRAF-mutant metastatic melanoma91. 
When these Raf inhibitors were evaluated in RAS-mutant cancer cells, paradoxically, 
activation rather than inactivation of ERK was seen92–94, as was also documented years 
earlier with a preclinical agent95. Raf dimerization, mediated by active Ras, causes 
activation of Raf, and these first generation Raf inhibitors promote Raf dimerization96,97. 
This accounts for the Raf inhibitor-induced development of benign skin tumours including 
keratoacanthomas and of squamous cell carcinomas of the skin when mutant RAS is present. 
Both second generation Raf inhibitors that exhibit pan-Raf activities and/or do not promote 
Raf dimerization, as well as inhibitors designed to block dimerization, are now under 
consideration; these may prove more efficacious in the long run98.
At least 15 MEK inhibitors have reached clinical evaluation (FIG. 4), with trametinib 
(GSK112021) recently approved by the US FDA for BRAF-mutant metastatic melanoma. 
Generally, the majority of these inhibitors acts as allosteric non-ATP competitive inhibitors 
of MEK1 and MEK2 and consequently are highly selective. Although MEK inhibitors have 
been effective against BRAF-mutant melanoma, they have been only partially effective in 
RAS-mutant cancers and human tumour cell lines 99 and in mutant RAS-driven mouse 
models of cancer100. Interestingly, the activation state of MEK and the mechanisms by 
which it is activated in RAS- versus BRAF-mutant cancers are distinct, and one recent study 
suggested that this in turn influences the response to specific MEK inhibitors101. For 
example, MEK inhibitors that act similarly to GDC-0623 and G-573 are likely to be more 
effective in RAS-mutant cancers, because they form a strong hydrogen bond with MEK 
S212 and block MEK feedback phosphorylation by Raf, whereas those that act similarly to 
cobimetinib (GDC-0973) are better at inhibiting active, phosphorylated MEK101. The dual 
Raf/MEK inhibitor RO5126766 can act in a similar manner102. Innate or acquired resistance 
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of RAS-mutant cancer cells to MEK inhibitors can occur by upregulation of receptor tyrosine 
kinase activity103 or by amplification of upstream activators104 that enhance flux through 
the pathway to elevate ERK activity above the >80% suppression threshold needed to 
achieve a therapeutic response105.
Since innate/de novo or acquired mechanisms of resistance to Raf or MEK inhibitors are 
often due to reactivation of ERK, one obvious approach to address this limitation is to use an 
ERK inhibitor. Currently, three ERK inhibitors have entered clinical evaluation (FIG. 4) and 
an analog of one (MK-8353/SCH9000353) has characterized in preclinical models106. 
However, like MEK inhibitors, ERK inhibitors also block ERK feedback phosphorylation 
and inactivation of Raf, leading to enhanced MEK activation. Combination inhibition of the 
Raf-MEK-ERK cascade at multiple nodes may provide more effective inhibition while 
reducing toxicity.
PI3K-AKT-mTOR inhibitors
The second best validated class of Ras effectors is comprised of the p110 catalytic subunits 
(α, γ and δ) of class I phosphoinositide 3-kinases (PI3Ks). The frequent mutational 
activation of PIK3CA (encoding p110α; 12%, COSMIC) and inactivation of the PTEN 
tumour suppressor support a driver role for PI3K in Ras-dependent cancer growth. Since 
PI3K activity can also be modulated by non-Ras mechanisms, Downward and colleagues 
applied an innovative approach to assess the importance of Ras-dependent PI3K activation 
alone. They generated mice harboring a mutant germline Pik3ca allele encoding a p110α 
variant with point mutations in the Ras-binding domain that prevent Ras-mediated activation 
but retain non-Ras-dependent activities107,108. Near-complete ablation of tumour initiation 
and partial regression of tumour growth was observed in a Kras-driven mouse model of lung 
cancer, indicating that K-Ras requires p110α in this setting. A similar partial reduction in 
tumour growth was seen upon pharmacologic inhibition of p110α. The importance of 
continued PI3K activity in tumour maintenance was also demonstrated in KRAS-mutant 
human tumour cells, where activated p110α was able to substitute for the loss of mutant 
KRAS to maintain tumour growth9. While the results from mouse model analyses provide a 
compelling argument that PI3K inhibition may be an effective anti-Ras strategy in some 
settings, there is also evidence that PI3K is not always a key Ras effector. Pharmacologic 
inhibition of this pathway in Kras-driven mouse lung cancers did not effectively block 
tumour growth100. Furthermore, KRAS silencing in KRAS-mutant colorectal cancer cell lines 
did not reduce activation of the PI3K effector AKT, although it effectively reduced ERK 
activation109; instead, increased receptor tyrosine kinase signalling accounted for the 
maintenance of AKT activation109. Finally, in contrast to the nonoverlapping BRAF and 
RAS mutations seen in human cancers, PIK3CA and RAS mutations often are seen together. 
Although correlative, this pattern suggests that mutated Ras alone may not potently activate 
PI3K signalling. Nevertheless, targeting PI3K-AKT signaling in RAS-mutant cancers, 
particularly in combination with other pathways, may have therapeutic value.
Currently, at least 53 inhibitors of PI3K-AKT-mTOR signaling are under clinical evaluation 
(FIG. 4). As monotherapy, these have shown disappointing activity against RAS-mutant 
cancers in preclinical and clinical evaluation. However, in mouse models, potent synergistic 
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activity with inhibitors of ERK-MAPK signalling has been seen100. Currently, there are 
numerous clinical trials evaluating combined inhibition of Raf and PI3K effector 
signalling110.
Ral inhibitors
RalGEFs comprise the third best validated effectors of Ras-driven cancer growth111,112. 
Mice deficient in RalGDS, one of the four RA domain-containing RalGEFs, were viable but 
displayed reduced carcinogen-induced mutant Hras-driven skin tumour formation113. 
Another RalGEF, Rgl2, was found overexpressed in KRAS-mutant colorectal cancer cell 
lines, and shRNA-mediated suppression of Rgl2 reduced Ral-GTP levels and impaired cell 
growth in vitro114. RalGEFs are activators of two related isoforms, RalA and RalB, and 
shRNA-mediated silencing of RalA and/or RalB in KRAS-mutant pancreatic cancer cell 
lines impaired growth. Interestingly, in the majority of cell culture studies, RalA and RalB 
exhibit very distinct roles in cancer cell behaviour. For example, RalA but not RalB was 
found to be necessary for the tumourigenic growth of pancreatic cancer cell lines, whereas 
RalB was important for invasion in vitro and experimental metastasis in vivo115. In contrast, 
in conditional tissue-specific genetic ablation studies, loss of both RalA and RalB was 
required to reduce Ras-driven lung or skin tumour growth116. These findings may reflect 
different roles for Ral GTPases in tumour initiation and progression versus maintenance, or 
cancer-type differences.
Like Ras, the Ral GTPases are not considered tractable drug targets. Therefore, current 
directions for therapeutic inhibition of Ral involve protein kinases that either modulate Ral 
subcellular localization and effector utilization or that act as downstream effectors. 
Analogous to PKCα phosphorylation of K-Ras4B, Aurora A and PKCα phosphorylate C-
terminal serine residues in RalA and RalB, respectively, which promotes their driver 
functions in cancer growth117–120. RalB effector signalling can lead to activation of the 
TBK1 serine/threonine kinase or the mTORC1 serine/threonine protein kinase 
complex121,122. Thus, protein kinase inhibitors may provide promising directions for 
blocking aberrant Ral GTPase signalling downstream of Ras.
Rac1 inhibitors
The fourth best validated effector of Ras-driven cancer growth is the Rac1 small GTPase123. 
Ras can activate RacGEFs and subsequently Rac1 through direct effector binding (e.g., 
Tiam1)124 or indirectly through PI3K activation (e.g., P-Rex)125. The importance of Rac1 as 
a critical driver of cancer growth is supported by the recent identification of activated RAC1 
mutations in cutaneous melanomas126,127. That inhibition of Rac1 may have a therapeutic 
benefit in RAS-mutant cancers is supported by mouse model studies in which genetic 
ablation of Rac1 function impaired initiation of mutant KRAS-driven lung or pancreatic 
cancers128,129. However, like Ras, Rac1 is a small GTPase, and therefore whether direct 
Rac1 inhibitors can be developed is still unclear. One small molecule inhibitor of Rac1 
activation by RacGEFs has been described130,131, suggesting that it may be feasible to 
develop inhibitors of Rac1 activation. Alternatively, analogous to current approaches for 
Ras, inhibitors of Rac1 effector signalling may be more tractable. However, of the many 
Rac1 effectors identified, which of them are essential drivers of Rac1-dependent growth 
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remains unanswered. The PAK1 serine/threonine kinase, found overexpressed in many 
cancers, is one possibility. Genetic ablation of Pak1 suppressed Kras-induced lung tumour 
formation in mice, and pharmacologic inhibition of PAK1 phenocopied loss of Pak1 
function132. In addition, the p110β isoform of PI3K was recently found to serve as an 
effector for Rac1 rather than for Ras133, providing another candidate effector of Rac1-
dependent cancer growth.
While other Ras effectors (e.g., phospholipase C ε, RASSF1) have demonstrated roles in 
cancer cell proliferation, these may not act as drivers of Ras-dependent cancer growth and 
hence their therapeutic value is presently unclear134.
In summary, while effector inhibition appears to be the most promising anti-Ras strategy to 
date, significant challenges remain. First, inhibition of any one effector pathway is 
complicated by compensatory mechanisms, necessitating inhibition at multiple points. 
Second, because multiple effectors have driver roles, concurrent inhibition of multiple 
pathways will be needed. This has prompted both preclinical and clinical evaluation of 
combining inhibitors of components of the Raf and/or PI3K effector networks. However, as 
the combinations are expanded to achieve more effective blockage of effector signalling, the 
offsetting increase in normal cell toxicity may tip the balance and cause loss of the 
therapeutic window. How to properly strike this balance is another provocative question for 
the future.
Synthetic lethal interactors of mutant RAS – needles in the haystack?
One possible approach to increasing therapeutic selectivity for cancer cells would be to 
identify targets that have synthetic lethal interactions with the RAS oncogene; that is, genes 
whose loss of function would be lethal only in the presence of mutated RAS (FIG. 5). 
Widespread observations of synthetic lethality in lower organisms suggested that genetic 
buffering, where one or more genes can functionally compensate for mutations in another 
gene, may be common135, and that synthetic lethal interactions might be exploitable for 
cancer treatment136. This approach could be particularly useful in situations where 
pharmacological action cannot be taken against the oncogenic mutations themselves, as in 
the case of RAS mutations.
The existence of oncogene-specific synthetic lethal interactions is supported by the fact that 
oncogenic mutations lead to prominent phenotypic changes in cancer cells, collectively 
known as the ‘hallmarks of cancer’137–139, where normal cellular pathways are co-opted, 
either directly or indirectly, to support the malignant growth of cancer cells. This often 
manifests in one of two ways. First, oncogenic transformation leads to elevated cellular 
stress (oncogenic stress), which requires the cancer cell to activate cellular stress-relief 
pathways for survival. Second, cancer cells often adapt their signalling pathways and alter 
their metabolic flux to support proliferation, and this requires compensatory changes in 
pathways not directly downstream of the driver oncogene. Collectively these “non-oncogene 
addictions” constitute potential synthetic lethal interactions (FIG. 5) that may be exploitable 
for therapeutic intervention139. The potent effect of PARP inhibitors in BRCA-mutant 
cancers is an example of exploiting synthetic lethality; BRCA1/2 mutations result in 
Cox et al. Page 17













deficiencies in DNA homologous recombination repair and render the cell particularly 
dependent on PARP-mediated non-homologous end-joining DNA repair for genomic 
stability.
Screen results
A number of studies have applied RNAi screens in human cancer cell lines to identify 
synthetic lethal interactors with the KRAS oncogene (reviewed in Ref. 140). Screens done 
with a variety of siRNA and shRNA libraries, whether in a well-by-well or a pooled format, 
have confirmed that many KRAS-mutant cell lines are indeed functionally addicted to the 
KRAS oncogene. These screens have identified a wide array of synthetic lethal interactions 
with mutant KRAS (TABLE 2) that encode proteins that can be thematically categorized into 
several cellular processes: cell cycle and mitosis (Survivin/BIRC5, TPX2, PLK1, APC/C), 
cell survival (WT1, Bcl-XL1), collaborative transcriptional programs (GATA2, SNAIL2), 
and parallel growth and survival signals (TBK1, TAK1) (FIG. 5). Whereas the roles of 
mutant KRAS in cell proliferation, genomic instability and apoptosis have been described 
previously141, the findings of KRAS dependency on kinases such as TBK1129 and 
transcription factors such as GATA2142 indicate that additional cellular pathways are 
involved in supporting the viability of KRAS-transformed cells. Thus far none of the 
synthetic lethal interactors has been found to be equal or superior to KRAS itself at 
discriminating KRAS-mutant and -WT cells.
In general the overlap among the hits from different KRAS synthetic lethal screens has been 
small, although proteasome subunits have been identified in three screens143–145. The lack 
of significant overlap can be attributed to several factors. The patterns of non-oncogene 
addictions in the presence of the common KRAS driver oncogene – and therefore the 
synthetic lethal interactions identified – may be context-dependent. Cancer cells harbour 
multiple oncogenic mutations2, and secondary mutations could alter the patterns of genetic 
dependency146,147. In addition, tumours arising from different organs display distinct 
lineage phenotypes despite harbouring similar oncogenic mutations148; thus, KRAS 
mutations could drive genetic dependencies in a tissue-specific fashion. All of these factors 
could cooperate with KRAS in determining the landscape of non-oncogene addictions in 
cancer cells. If the landscape is indeed this fragmented, “universal” KRAS synthetic lethal 
interactors might be difficult to identify.
Improving the screen
Although the first generation of KRAS synthetic lethal screens has revealed interesting 
biological information about KRAS-mutant cancers, the findings have suffered from a 
number of technical limitations that have reduced confidence in the applicability of their 
results going forward. The most prominent of these limitations is the lack of library 
validation, which could contribute to high false-negative rates in the screen. In addition, 
library penetrance (i.e., the number of siRNA/shRNAs that effectively knock down a given 
gene) is highly variable among the different libraries, which could also lead to high and 
variable false-negative rates. A new generation of libraries with multiple validated si/
shRNAs per gene would significantly improve the penetrance of the screen and would also 
make it easier to rule out off-target effects, thereby decreasing the false-positive rate. 
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Furthermore, a validated library is likely to be more widely adopted by the research 
community, thus making cross-study comparisons easier. Finally, due to cost and feasibility 
issues, first-generation synthetic lethal screens were typically carried out using either KRAS-
isogenic cell lines or a small panel of KRAS-mutant and -WT cell lines. While isogenic cell 
lines can useful for isolating the effect of individual oncogenes, care should be taken to 
recognize their limitations. For example, introduction of mutant KRAS into WT cells may 
not necessarily confer KRAS oncogene addiction. Conversely, loss of mutant KRAS might 
force any surviving cells that are now KRAS WT to compensate by upregulating other 
pathways to which they then become addicted, such as the transcriptional coactivator 
Yap1149,150.
Efforts to screen large panels of cancer cell lines are underway, which should more 
thoroughly take into account the heterogeneity among KRAS-mutant cell lines due to 
different lineages and co-existing mutations151,152. Indeed, a recent siRNA analysis of a 
large number of lung cancer cell lines revealed that the majority of genetic dependencies are 
“private” to individual cell lines and only a minority of genetic dependencies are shared 
“publicly” among many cell lines147. Screening a very large cell line collection such as the 
Cancer Cell Line Encyclopedia153 would also be useful to determine the landscape of KRAS 
synthetic lethality in a context-dependent fashion. Finally, all currently described synthetic 
lethal screens were conducted in vitro using anchorage-dependent proliferation or viability 
as the readout. Second generation synthetic lethal screens could benefit from other assay 
formats such as in vitro anchorage-independent colony formation assays or in vivo xenograft 
tumour assays that better interrogate the tumourigenic capability of the KRAS oncogene. 
Both of these types of assays have been successfully adapted for high-throughput 
screening154–157. However, these assays are likely to be less robust and their execution 
requires considerable effort; hence, knockdown-validated shRNA libraries would be 
particularly useful in these screens.
Compared to in vitro viability assays of cells cultured on plastic, in vivo screening has the 
benefit of providing a more physiological setting and the potential to reveal genes that are 
required only for tumor growth but not for cancer cell proliferation in vitro. Pooled shRNA 
libraries have been successfully applied in vivo for both enrichment screens to identifiy 
tumor suppressor genes158–160 and for dropout screens to identify tumour-essential 
genes155,157. By using syngeneic mouse cancer cells155,160, in vivo screening also has the 
potential to address the roles of the microenvironment and immune interactions in tumour 
growth.
From a therapeutic point of view, targeting synthetic lethality should provide a work-around 
solution to an undruggable oncogene. However, KRAS synthetic lethal interactors from the 
first generation of screens may not serve as ideal candidates for drug discovery: targeting the 
cell cycle machinery could lead to significant toxicity in normal proliferating tissues, 
whereas transcription factors such as GATA2 are themselves undruggable and require 
indirect targeting strategies161. Although the protein kinase STK33 was initially proposed to 
be a druggable target in KRAS-mutant cells144, subsequent studies found that neither genetic 
or pharmacologic inhibition of STK33 selectively inhibited the growth of such cells162. 
Genetic and pharmacologic evaluations of TBK1 found no consistent requirement for TBK1 
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in the growth of KRAS-mutant tumour cell lines in vitro163, although combined TBK1 and 
MEK inhibition led to partial regression of Kras;p53 mutant lung tumours in mice164. This 
result highlights a limitation of high throughput screening - hits must be rigorously 
validated. Further effort is therefore necessary to identify better synthetic lethal candidates 
for drug discovery. However, given the uncertain success of current strategies for targeting 
K-Ras effector signalling, synthetic lethal screening may still be a valuable approach to 
broaden the target space for discovering therapeutic approaches that are orthogonal to Ras 
pathway inhibitors. One recent study determined that combined targeting of both MEK and 
BCL-XL led to synthetic lethality and improved therapeutic efficacy over loss of either 
alone, with tumour regressions obtained in both KRAS-driven xenografts and a genetically 
engineered mouse model of lung cancer165.
An exciting recent development in genetic screening is the adaptation of the bacterial Type 
II CRISPR-Cas9 system for genome editing in mammalian cells166. In this method, a short, 
20-nucleotide single guide RNA (sgRNA) guide sequence directs the RNA-dependent 
DNase Cas9 to cleave any target gene bearing sequence homology to the sgRNA. Imprecise 
double-strand DNA repair through non-homologous end-joining subsequently leads to 
insertion or deletion mutations that knock out gene expression. Like RNAi, CRISPR relies 
on short-length sequence homology and therefore could suffer from similar off-target 
effects. However, unlike RNAi, which produces various degrees of hypomorphic 
phenotypes, CRISPR generates true nulls when designed properly, thus vastly improving 
library penetrance. Pooled CRISPR libraries have been deployed for genetic screens in 
human cell lines167,168 and this approach is likely to provide an orthogonal, and potentially 
superior, alternative to RNAi screens in the search for mutant RAS synthetic lethal 
interactions. A recent CRISPR screen in a melanoma model identified both previously 
validated and novel genes whose loss promoted resistance to the B-Raf inhibitor 
vemurafenib167.
Ras-driven changes in metabolism – ready for prime-time?
In order to meet the increased biosynthetic demands of a growing tumour, cancer cells alter 
their metabolism. Metabolic changes were first observed in pioneering research in the 1920s 
by Otto Warburg, when he demonstrated that tumour cells take up excess glucose and 
produce lactate even in the presence of oxygen (aerobic glycolysis, a.k.a. the Warburg 
effect)169. Today, these metabolic adaptations, including the Warburg effect, are now 
recognized as one of the hallmarks of cancer138,139. One of the major requirements of 
tumour cells, given their deregulated proliferation, is the need to increase biomass. Thus, 
there is a shift towards anabolic metabolic processes to produce building blocks such as 
amino acids, nucleic acids, lipids and cofactors such as NADPH for redox balance and 
reductive biosynthesis170–172. While much is known about the altered metabolism of tumour 
cells, more recent work has shown that many of the metabolic changes seen in these cells are 
brought about on a molecular level by oncogenes and tumour suppressor genes173–175. 
Indeed, oncogenic Ras has been shown to be a key player in promoting such metabolic 
rewiring, although the specifics may differ depending on tumour type and genetic 
context15,176. Importantly, many of the metabolic changes driven by oncogenic Ras become 
critical for tumour maintenance and thus become attractive therapeutic targets in their own 
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right. Additionally, because they are not dependent on oncogenic Ras, normal tissues often 
do not have the same reliance on such pathways and therefore there is potential for a 
tractable therapeutic index. The fact that metabolic reactions are enzyme-mediated also 
presents the opportunity to inhibit their catalytic activity with small molecules. Here we 
review the metabolic changes driven by oncogenic Ras and explore the therapeutic 
possibilities of targeting these pathways in various tumour types.
Metabolic recycling
One of the convergent themes in the metabolism of Ras-driven cancers is that they have 
developed a reliance on several mechanisms to either recycle intracellular fuel sources or 
scavenge extracellular constituents to meet their metabolic needs177. One such process is 
macroautophagy (hereafter referred to as autophagy), a process of self-eating, whereby 
intracellular substrates are sequestered in double-membrane vesicles known as 
autophagosomes178 (FIG. 6). These autophagosomes can fuse to lysosomes, forming 
autophagolysosomes, where the cargo is degraded by lysosomal hydrolases and then 
recycled back into the cytoplasm to be used in various metabolic reactions178. In cancer the 
role of autophagy is complex and context-dependent179–181; however, growing evidence has 
shown that in certain tumour types such as those driven by oncogenic Ras, autophagy is 
required for tumour maintenance in large part to fuel the metabolism of these aggressive 
cancers182–185. Indeed, inhibition of autophagy in this context either genetically or 
pharmacologically causes metabolic dysfunction and a decrease in tumour growth. There 
have been suggestions that the tumour suppressor gene background may dictate the role of 
autophagy in a given tumour type harbouring activating KRAS mutations. However, there 
are conflicting data in this regard that could be due to differences in the various models used 
as well as to other factors186–188.
Chloroquine and its derivative hydroxychloroquine (HCQ) can act as autophagy inhibitors, 
given their ability to inhibit lysosomal acidification189,190. Since they are already approved 
for use in patients for other indications and have been used safely for several decades, these 
drugs have now made their way into multiple clinical trials in various cancer types. Ras-
driven cancers such as pancreatic cancer, in which nearly 100% of tumours possess 
activating KRAS mutations191, are highly represented in these trials. While HCQ has been 
shown to be effective in the preclinical setting, there are many questions regarding its use in 
patients, including its pharmacological properties (a long period of time is required to reach 
therapeutic levels) as well as its low potency189. Furthermore, as these drugs work at the 
level of the lysosome to inhibit the degradation of autophagosomal contents, they likely will 
interfere with other cellular processes. However, this may have anti-tumour benefits in that 
other processes such as macropinocytosis (discussed below) converge at the level of the 
lysosome. Whether HCQ is potent enough to inhibit autophagy in human tumours remains 
to be seen, and more potent autophagy inhibitors are in development. Given the multiple 
kinases involved in the process, as well as key components analogous to the ubiquitin 
conjugation system, there are several potential opportunities for drug development to inhibit 
this pathway192.
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In addition to autophagy, which can generate metabolic substrates through intracellular 
degradation, Ras-transformed cells have developed other adaptations to essentially engulf 
extracellular proteins. It has been known since the 1980s that cells expressing Ras 
oncogenes undergo a process known as macropinocytosis, whereby a membrane process 
envelopes extracellular contents193. This is then internalized and ultimately fuses to the 
lysosome, where, in a process similar to autophagy, the contents of the macropinosome are 
degraded. Unlike autophagy, where much of the machinery has been identified, much less is 
known about the proteins that are critical for macropinocytosis194. Regardless, recent work 
has shown that, in the context of KRAS-mutant cancer cells, macropinocytosis may be 
playing a key metabolic role. Indeed, K-Ras-transformed cells, including pancreatic cancer 
cells, utilize macropinocytosis to uptake extracellular albumin which is then degraded into 
amino acids and used to fuel the TCA cycle195. In addition to proteins, Ras-transformed 
cells take up extracellular lipids and use these as their major source of fatty acids196. 
Together, these data show that Ras-driven cancers utilize multiple mechanisms to scavenge 
various metabolites and that there may be therapeutic opportunities in this regard as normal 
cells are not likely to be as reliant on these metabolic adaptations. In particular, as autophagy 
and macropinocytosis converge at the level of the lysosome, targeting degradation using 
HCQ or related inhibitors may have clinical utility and such trials are underway.
Targeting metabolic changes
Several recent studies have shown that one of the major mechanisms by which oncogenic K-
Ras promotes tumour growth is by rewiring key aspects of metabolism in tumours. Mutant 
K-Ras has been shown to increase glucose uptake, and conversely low glucose conditions 
can select for tumour cells with KRAS mutations197. Work in pancreatic cancer systems has 
shown that oncogenic K-Ras systematically controls glucose metabolism by promoting a 
transcriptional program that leads to alterations of key rate-limiting enzymes of anabolic 
glucose metabolism15 (FIG. 6). The net result of these changes is increased flux of 
glycolytic intermediates through pathways such as the hexosamine biosynthesis pathway 
(HBP) and the non-oxidative arm of the pentose phosphate pathway (PPP). This leads to 
increased production of precursors used for glycosylation (HBP) and ribose used for DNA 
and RNA biosynthesis (non-oxidative PPP). Importantly, inhibition of either of these 
pathways using shRNAs to the K-Ras-regulated enzymes inhibits pancreatic cancer growth 
in vitro and in xenografts15. While no inhibitors of these enzymes are currently available, 
studies of K-Ras signalling pathways that mediate the transcriptional and metabolic changes 
in anabolic glucose metabolism have provided a potential therapeutic approach. Indeed, the 
Raf-MEK-ERK pathway was shown to be critical for the metabolic shift caused by 
oncogenic K-Ras15. Clinical grade inhibitors of MEK are being tested in a variety of cancers 
and it may be possible to attenuate anabolic glucose metabolism in K-Ras mutant cancers 
with these compounds. Other studies have supported the approach of inhibiting various 
aspects of glucose metabolism in KRAS–driven tumours, including inhibition of lactate 
dehydrogenase198 and hexokinase 2199.
In addition to glucose metabolism, oncogenic K-Ras appears to orchestrate a shift in 
glutamine metabolism in pancreatic and other cancer types176,200,201. In pancreatic cancers, 
K-Ras appears to coordinate transcriptional changes that result in a net increase in flux 
Cox et al. Page 22













through a novel pathway, whereby glutamine-derived aspartate is converted to oxaloacetate 
by the cytosolic aspartate aminotransferase (GOT1), then to malate by malate 
dehydrogenase (MDH1), and finally to pyruvate and NADPH by the cytosolic malic enzyme 
(ME1) (FIG. 6). The NADPH generated from this series of reactions is critical for growth 
because of its role in maintaining reduced glutathione pools for redox balance176. 
Importantly, this pathway was shown to be required for pancreatic cancer redox balance and 
growth in vitro and in vivo, while being dispensable in normal cells, thus implying that a 
therapeutic index may exist. Currently, there are no clinical grade inhibitors of GOT1/2, 
MDH1, or ME1 available. However, inhibitors of glutaminase (GLS), the enzyme that 
catalyzes the conversion of glutamine to glutamate, are available and are making their way 
into early phase clinical trials202. GLS inhibitors alter the redox balance in pancreatic cancer 
cells and synergize with treatments that increase reactive oxygen species (ROS) to inhibit 
pancreatic cancer growth176. Thus, there is potential to combine GLS inhibitors with 
treatments such as radiotherapy and chemotherapies that increase ROS. An important 
question remains as to whether these K-Ras-regulated glucose and glutamine pathways are 
specific to pancreatic cancers or are a common feature of all Ras-driven tumours. Such 
studies are ongoing. In this regard it has been reported that inhibition of the aspartate 
aminotransferase in a breast cancer cell line harboring a KRAS mutation has anti-tumour 
effects203.
An interesting theme emerging from studies of the metabolic changes driven by oncogenic 
KRAS is that this oncogene also has a prominent role in maintaining redox balance. This 
may be through the control of metabolic pathways that lead to increased NADPH production 
as mentioned above176,200 or alternatively through other mechanisms such as the 
upregulation of NRF2, a master regulator of redox defense204. Indeed, it was demonstrated 
that oncogenic K-Ras, when expressed at endogenous levels, leads to decreased ROS levels 
in multiple cell types through the induction of the NRF2 antioxidant program205. However, 
there is also evidence suggesting that KRAS-driven tumourigenesis requires ROS201. 
Therefore, it is likely that keeping a controlled level of ROS is beneficial for tumour growth 
whereas disrupting redox homeostasis in K-Ras-driven tumours may be an effective 
therapeutic strategy.
In conclusion, mounting evidence demonstrates that one of the mechanisms by which 
oncogenic Ras supports tumour growth is through altering the metabolism of cancers to suit 
its needs. In many cases, these pathways remain critical to tumour growth and therefore may 
provide tractable therapeutic opportunities for future drug development initiatives. While we 
await the development of novel inhibitors to various metabolic enzymes, some, such as GLS 
inhibitors, are currently available for use. Additionally, understanding how available 
compounds perturb metabolic pathways may allow a more rapid translation of preclinical 
findings to the clinic. Examples of new uses for older drugs include HCQ to inhibit 
autophagy and macropinocytosis, phenformin/metformin to inhibit mitochondrial complex I, 
and MEK inhibitors to globally inhibit anabolic glucose metabolism in pancreatic cancers.
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Conclusions and Future Prospects
As the general and military strategist Sun Tzu wrote in The Art of War, an influential ancient 
Chinese book on military strategy, success in battle is better achieved when we “know the 
enemy”. The more than three decades of intense research focussed on Ras have provided an 
ever-increasingly comprehensive description of the target — we have repeatedly thought 
that we knew our enemy, Ras. Nevertheless, we have repeatedly failed to realize that our 
understanding has been far from complete, and this failure has contributed to missteps and 
misdirections in anti-Ras drug development. Currently, we can at least recognize that issues 
once thought to be understood are clearly still works in progress. In particular, our view of 
Ras effector signalling, once thought to be a simple, linear unidirectional protein kinase 
cascade, has evolved to recognize a complex and highly dynamic signalling network that 
can adapt and rewire in response to pharmacologic inhibitors. Other issues that remain 
poorly understood, yet will have significant impact on successful anti-Ras drug 
development, also need resolution. One likely basis for the failure of anti-Ras drug 
discovery efforts is the still-prevalent assumption that activated Ras comes in one simple 
flavour. There is now at least a greater appreciation that the three RAS isoforms are not 
functionally equivalent, and that each will require distinct therapeutic approaches, resulting 
in the intense focus now on KRAS.
Along the lines of RAS isoform differences, there remain the issues of why KRAS is mutated 
far more frequently than the other RAS isoforms and why some types of cancer almost 
exclusively harbor mutations in KRAS but not in the other RAS isoforms. In one study, this 
issue was addressed using a mouse model where carcinogen-induced lung tumour formation 
is associated with a high frequency of Kras mutations206. In a mouse where the genomic 
Kras locus was genetically engineered to express the H-Ras protein instead, lung tumours 
arose at an even higher incidence and had Hras mutations. This result argues that it is not 
the Ras protein itself, but rather the Kras regulatory locus, that favours KRAS mutations in 
human lung tumours. In contrast to this suggestion, a recent provocative study found that 
KRAS contains a high frequency of rare codons relative to HRAS, resulting in reduced 
protein translation207. When the KRAS gene was modified with more commonly used 
codons, K-Ras protein expression was significantly higher and exhibited more potent 
transforming activity. This result suggests that, since mutant Ras expression in normal cells 
lacking other genetic alterations causes senescence, low K-Ras protein expression favours 
the persistence of histologically normal cells harbouring mutant KRAS, thereby allowing 
subsequent genetic events that then drive cancer progression. Then, once progression is 
initiated, higher mutant K-Ras expression is needed to drive cancer growth; this may explain 
the KRAS gene amplification often seen in cancers. A critical validation of this hypothesis 
would be a reduced incidence of tumour formation induced by mutant Kras in a mouse 
harbouring an endogenous codon-optimized Kras locus.
With the predominant frequency of KRAS mutations in human cancers, in particular in 
cancers in dire need of improved therapies, the focus is now strongly on K-Ras. Since earlier 
studies had found that the KRAS4B splice variant is preferentially expressed, this focus is 
currently most centered on the K-Ras4B protein. However, whether K-Ras4A should still be 
considered a key player in cancer remains a neglected issue208. KRAS was originally 
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discovered to be an oncogene when Werner Kirsten identified a murine leukaemia virus that 
transduced the rat cellular Kras gene. That this gene encodes K-Ras4A is perhaps a reminder 
that this splice variant should not be ignored completely. Indeed, new unpublished data 
indicates that K-Ras4A is more widely expressed in human cancers than previously 
appreciated and could also contribute to the transformed phenotype (Philips, Cox et al.).
Another less-appreciated possibility is that different KRAS mutations have distinct 
oncogenic properties and hence may be differentially responsive to targeted therapies. This 
possibility is suggested by the finding that patients with colorectal cancer whose tumours 
harbor KRAS G13D mutations, in contrast to G12 mutations, showed a clinical benefit from 
cetuximab anti-EGFR therapy209,210. Similarly, in cell culture and mouse model analyses, 
G13D but not G12V colorectal cancer cells were sensitive to cetuximab. In a study of 
NSCLC, it was found that tumours with either KRAS G12C or G12V mutations correlated 
with worse progression-free survival compared to tumours with WT or other KRAS 
mutations211. A possible functional basis for this correlation was suggested by the finding 
that NSCLC cell lines with KRAS G12D preferentially activated the Raf and PI3K effector 
pathways, whereas those with KRAS G12C or G12V preferentially activated the Ral effector 
pathway. These and other studies have stimulated an awareness that we may need to pursue 
mutation-specific anti-Ras strategies, and this awareness is reflected in the fact that the NCI-
directed Ras Initiative has identified KRAS G12D, G12V, G12C and G13D as the four 
mutant proteins to target. However, any additional genetic alterations that co-occur with one 
specific KRAS mutation will also diversify the therapies required in order to be effective. 
WT Ras activation by indirect mechanisms, whether by upstream receptor tyrosine kinase 
activity or by the loss of RasGAP function will also likely require very distinct therapeutic 
approaches. Hence, one therapy will not fit all flavours of activated Ras, and there will not 
be one simple anti-Ras drug for all situations.
Perhaps one of the more perplexing issues that remains far from understood today is the role 
of wild type Ras in the setting of mutant Ras. This issue has two seemingly conflicting 
camps. On one hand, there is evidence that wild type KRAS can act as a tumour suppressor 
and antagonize mutant KRAS oncogenicity212,213–215. Consistently, a significant subset of 
KRAS-mutant tumour cell lines is homozygous for the mutant allele. But how might wild 
type KRAS antagonize mutationally activated KRAS – is the GDP-bound form of K-Ras not 
simply an inactive protein? There are clues that Ras proteins may dimerize216; perhaps a 
WT:mutant K-Ras dimer is inactive. However, this tumour suppressor function may not 
hold true for WT NRAS217. In contrast to the above noted support for WT KRAS as a tumour 
suppressor, other studies have found instead that WT RAS isoforms serve a supporting role 
for the mutated RAS isoform75,218,219. Here, there is strong experimental evidence to 
support the necessity of the WT isoform in the context of the mutated isoform. However, the 
mechanistic relationship between them and what activated wild type Ras does that cannot be 
fulfilled by the mutated Ras isoform remain unclear.
There are other challenges: even if an inhibitor can be developed that effectively blocks 
mutant Ras function and has a significant therapeutic response, compensatory mechanisms 
will likely be triggered to overcome the RAS addiction of cancer cells, and such newly RAS-
independent cancer cells will likely drive the return of cancer growth149,150. This notion is 
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supported by the fact that mutant Ras-driven cancer growth involves effector signalling 
networks that can also be activated by Ras-independent mechanisms. A clear understanding 
of the mechanistic basis for such resistance will be required to successfully overcome it, 
perhaps by prompting effective rational combinations of therapies, whether these be 
conventional and targeted drugs or targeted inhibitors and synthetic lethal interactors165.
An emerging and exciting new direction may come from recent advances in our 
understanding of the immunological underpinnings of the activities of mutant RAS220. For 
example, mutant K-Ras induces granulocyte-macrophage colony-stimulating factor (GM-
CSF) secretion in mouse pancreatic tumour cells, stimulating the expansion of 
immunosuppressive myeloid-derived suppressor cells (MSDCs) and blocking T cell-driven 
anti-tumour immunity221,222. This altered cytokine expression and/or the MSDCs 
themselves might be exploitable for immunotherapeutic attack. Similarly, one focus of the 
NCI Ras Project involves mapping the surface of mutant K-Ras to identify sites of tumour-
selective immune recognition.
Finally, silencing of RAS by interfering RNA is another possible future direction. While still 
not ready for prime time, progress continues to be made in addressing key limitations of 
RNAi-based therapy, particularly to facilitate efficient delivery to and entry into tumour 
cells, and to obtain the effective and prolonged gene suppression that will be required to 
achieve a clinical response223.
In summary, while the task of developing effective therapeutic strategies for Ras-dependent 
cancers remains a daunting initiative, with new knowledge and strategies, there is cautious 
optimism that what has been an impossible mission may become Mission Possible.
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Figure 1. Approaches to discover and develop pharmacologic inhibitors of mutant Ras
Past and ongoing approaches to inhibitors of mutationally activated Ras include Ras-binding 
small molecules that disrupt a key function(s) of Ras, inhibition of the CAAX motif-targeted 
enzymes that promote Ras membrane association, inhibitors of effector signalling function, 
unbiased interfering RNA, genetic or chemical screens for synthetic lethal interactors and 
inhibitors of metabolism.
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Figure 2. Compounds that have been reported to bind to Ras
SCH-53239 was designed to inhibit guanine nucleotide exchange27. Structure-activity 
relationship studies led to the development of a derivative with greater water solubility, 
SCH-54292. Subsequently, another group used molecular modeling to design a series of 
sugar-derived bicyclic analogs28. Based on earlier observations that the NSAID sulindac 
showed anti-tumour activity in Hras-mutant rat mammary carcinomas224, the active 
metabolite sulindac sulphide was evaluated and found to bind to H-Ras29. IND12 is a 
sulindac derivative that blocks the growth of Ras-transformed cells31,32. MCP1 was 
identified in a yeast two-hybrid screen for inhibitors of H-Ras binding to full length Raf-134. 
Zn-cyclen selectively binds and stabilizes the weak effector binding affinity conformational 
state of Ras35. The HBS3 peptide is a mimic of the Sos1 αH helix that interacts with H-
Ras36. DCAI and VU0460081 were identified in fragment-based library screens for K-
Ras4B-binding molecules35,36. Kobe0065 was identified in a computer docking screen of a 
virtual compound library and selected for its ability to inhibit H-Ras-GTP binding to Raf-
RBD40. Kobe2602 was identified in a subsequent computer-assisted similarity search of 
160,000 compounds. A K-Ras G12C inhibitor was identified using a disulphide-fragment-
based screening approach with GDP-bound K-Ras G12C. SML-8-73-1 covalently binds to 
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K-Ras G12C and occupies the nucleotide binding site44. The Nucleotide exchange activator 
(compound 4) stimulates Ras-GTP formation, yet disrupts ERK and PI3K signalling45.
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Figure 3. Three-dimensional structures of Ras/ligand complexes
Ras is represented as a molecular surface, the ligands are in stick models with yellow carbon 
atoms, and the nucleotide is in stick models with tan carbon atoms. The switch I region is in 
sky blue, and the switch II region is in purple. a | X-ray structure of a compound covalently 
linked to K-Ras G12D (PDB 4M22). GCP bound to DCAI (PDB 4DST)38. b | X-ray 
structure of K-Ras G12V. GDP bound to VU046000939. c | NMR-derived structure of K-
Ras T35S. GNP bound to Kobe 2601 (PDB 2LWI)40. d | X-ray structure of K-Ras G12C. 
GDP bound to Shokat compound (PDB 4M22)41.
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Figure 4. Inhibitors of RAS effector signalling under clinical evaluation
Compiled from clinicaltrials.gov. Ras proteins bind to the Ras-binding domain (RBD) of the 
p110 catalytic subunit of class I PI3Ks (α, γ, and δ). Unless indicated otherwise, PI3K 
inhibitors are pan-class I. Ras binds to the RBD of A-Raf, B-Raf and C-Raf. mTOR exists as 
two distinct complexes, mTORC1 (Raptor) and mTORC2 (Rictor). Rapamycin/sirolimus 
and its analogs (rapalogs: everolimus, ridaforolimus, and temsirolimus) are selective for 
mTORC1, forming a complex with mTOR and FKBP12. Second-generation mTOR 
inhibitors are ATP-competitive inhibitors of mTOR kinase activity.
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Figure 5. Synthetic lethal interactors in RAS-mutant cancers
Functional screens for mutant RAS synthetic lethal interactors utilize chemically synthesized 
siRNA libraries or viral vector-based shRNA libraries to identify genes whose knockdown 
causes selective impairment of the growth of RAS mutant but not RAS WT cell lines. The 
libraries may be either genome-wide or target a selected set of genes. The library may be 
delivered well-by-well, as shown in Panel A, or as pooled viruses. RAS synthetic lethal 
partners may operate in different pathways to support the viability of RAS mutant cells 
(Panel B). These include co-operating signalling and transcriptional programs, maintenance 
of genomic stability, and suppression of oncogenic stress.
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Figure 6. Ras-driven alterations in metabolism
RAS-mutant cancer cells are characterized by increased macropinocytosis and uptake of 
albumen, leading to lysosomal degradation and release of amino acids. RAS-mutant cancer 
cells also exhibit altered autophagy, leading to degradation of organelles and proteins, and to 
production of amino acids and other components that support metabolism. Oncogenic K-Ras 
directs glucose metabolism into biosynthetic pathways in PDAC by upregulating many key 
enzymes in glycolysis. Oncogenic K-Ras induces nonoxidative PPP flux to fuel increased 
nucleic acid biosynthesis and activates the hexosamine biosynthesis and glycosylation 
pathways. PDAC cells also utilize a non-canonical pathway to process glutamine and use it 
to maintain redox status and support growth. Blue text indicates Ras-dependent gene and/or 
protein expression, with arrows indicating increased (green) or decreased (red) expression. 
Enzymes are indicated in italics. Abbreviations used are: Glut1, glucose transporter 1; Hk 
1/2, hexokinase 1/2; Pfk1, phosphofructokinase 1; Eno1, enolase 1; Pkm, pyruvate kinase; 
Ldha, lactate dehydrogenase A; Gfpt1, glucosamine-fructose-6-phosphate 
aminotransferase-1; GlcN, glucosamine; GlcNAc, N-acetylglucosamine; Rpe, ribulose-5-
phosphate-3-epimerase; Rpia, ribulose-5-phosphate isomerase; GLUD1, glutamate 
dehydrogenase 1; GLS1, glutaminase 1; GOT1/2, aspartate transaminase 1/2; MDH1, malate 
dehydrogenase 1; ME1, malic enzyme; GSH, glutathione; GSSG, glutathione disulfide; 
ROS, reactive oxygen species.
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Table 1
Frequency of RAS mutations in human cancers
Cancer % KRAS % NRAS % HRAS % All RAS
Pancreatic ductal adenocarcinoma 97.7 0.0 0.0 97.7
Colorectal adenocarcinoma 44.7 7.5 0.0 52.2
Multiple myeloma 22.8 19.9 0.0 42.6
Lung adenocarcinoma 30.9 0.9 0.3 32.2
Skin cutaneous melanoma 0.8 27.6 1.0 29.4
Uterine corpus endometrioid carcinoma 21.4 3.6 0.4 24.6
Uterine carcinosarcoma 12.3 1.8 0.0 14.0
Thyroid carcinoma 1.0 8.5 3.5 13.0
Stomach adenocarcinoma 11.4 0.9 0.0 12.3
Acute myeloid leukaemia 3.1 6.7 1.6 11.4
Bladder urothelial carcinoma 3.1 1.4 5.9 10.6
Cervical adenocarcinoma 8.3 0.0 0.0 8.3
Head and neck squamous cell carcinoma 0.5 0.3 4.7 5.5
Gastric carcinoma 4.0 1.0 0.0 5.0
Esophageal adenocarcinoma 4.1 0.0 0.7 4.8
Chronic lymphocytic leukaemia 1.9 2.5 0.0 4.4
Lung squamous cell carcinoma 2.2 0.0 2.2 4.4
Small cell lung carcinoma 1.4 0.0 1.4 2.8
Renal papillary cell carcinoma 1.8 0.0 0.0 1.8
Adenoid cystic carcinoma 0.0 0.0 1.7 1.7
Medulloblastoma & pilocytic astrocytoma 1.0 0.5 0.0 1.6
Breast invasive carcinoma 0.7 0.4 0.3 1.4
Hepatocellular carcinoma 0.8 0.4 0.0 1.4
Cervical squamous cell carcinoma 1.3 0.0 0.0 1.3
Ovarian serous adenocarcinoma 0.6 0.6 0.0 1.3
Adrenocortical carcinoma 1.1 0.0 0.0 1.1
Neuroblastoma 0.0 0.8 0.0 0.8
Brain lower grade glioma 0.5 0.5 0.0 0.7
Prostate adenocarcinoma 0.3 0.0 0.3 0.7
Glioblastoma multiforme 0.7 0.0 0.0 0.7
Medulloblastoma 0.0 0.4 0.0 0.4
Kidney renal clear cell carcinoma 0.2 0.0 0.2 0.4
Esophageal adenocarcinoma 0.0 0.0 0.0 0.0
Osteosarcoma (paediatric) 0.0 0.0 0.0 0.0
Rhabdoid tumours 0.0 0.0 0.0 0.0
Sarcoma 0.0 0.0 0.0 0.0
Small intestine neuroendocrine tumours 0.0 0.0 0.0 0.0
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Cancer % KRAS % NRAS % HRAS % All RAS
T-cell prolymphocytic leukemia 0.0 0.0 0.0 0.0
Compiled from references or databases referred to in Supplementary Table 1
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